NX-5948

PARIS, Aug. 4, 2026 Sanofi announced that the European Commission (EC) has approved an expanded indication for MenQuadfi® (Meningococcal...

BRISBANE, Calif., Aug. 4, 2026 Nurix Therapeutics, Inc. announced the enrollment of the first patient in the registrational Phase...

Brisbane, California, USA | July 21, 2026 Nurix Therapeutics announced the official closing of its previously announced global collaboration...

BASEL, Switzerland, June 8, 2026 Roche announced a global licensing and collaboration agreement with Nurix Therapeutics to co-develop and...

BRISBANE, Calif., May 14, 2026 Nurix Therapeutics presented new preclinical and Phase 1 translational data at the Society for...

BRISBANE, Calif., May 12, 2026 Nurix Therapeutics announced that updated clinical data for its investigational BTK degrader bexobrutideg (NX-5948)...

BRISBANE, Calif., December 8, 2025 — Nurix Therapeutics has announced compelling new Phase 1 clinical data for its investigational...